Michael A. Postow, MD
Combination therapy continues to propel the treatment landscape for patients with melanoma in a positive direction, according to Michael A. Postow, MD, who adds that an area of interest is the combination of BRAF and MEK inhibitors with PD-1 therapy as well as combinations of LAG-3 inhibition plus PD-1 agents.
on Melanoma, Postow, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the evolution of combination therapies for patients with melanoma.
OncLive®: Please provide an overview of your presentation on combination therapies for patients with melanoma.
: There are many new combination therapies in patients with melanoma. For patients with BRAF-mutant melanoma, we are seeing combinations of BRAF and MEK inhibitors with immunotherapy drugs that are moving into randomized phase III studies. We will know if something improves when you add immunotherapy to BRAF and MEK inhibitors. Outside of that targeted therapy world for patients with BRAF-mutant melanoma, we are seeing new immuno-oncology combination agents.
... to read the full story